Search: id:"swepub:oai:DiVA.org:uu-401403" >
Fluoxetine for stro...
-
Mead, Gillian E.
(author)
Fluoxetine for stroke recovery : Meta-analysis of randomized controlled trials
- Article/chapterEnglish2020
Publisher, publication year, extent ...
-
2019-10-17
-
SAGE Publications,2020
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-401403
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-401403URI
-
https://doi.org/10.1177/1747493019879655DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:142106110URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
OBJECTIVE: To determine whether fluoxetine, at any dose, given within the first year after stroke to patients who did not have to have mood disorders at randomization reduced disability, dependency, neurological deficits and fatigue; improved motor function, mood, and cognition at the end of treatment and follow-up, with the same number or fewer adverse effects.METHODS: Searches (from 2012) in July 2018 included databases, trials registers, reference lists, and contact with experts. Co-primary outcomes were dependence and disability. Dichotomous data were synthesized using risk ratios (RR) and continuous data using standardized mean differences (SMD). Quality was appraised using Cochrane risk of bias methods. Sensitivity analyses explored influence of study quality.RESULTS: The searches identified 3414 references of which 499 full texts were assessed for eligibility. Six new completed RCTs (n = 3710) were eligible, and were added to the seven trials identified in a 2012 Cochrane review (total: 13 trials, n = 4145). There was no difference in the proportion independent (3 trials, n = 3249, 36.6% fluoxetine vs. 36.7% control; RR 1.00, 95% confidence interval 0.91 to 1.09, p = 0.99, I2 = 78%) nor in disability (7 trials n = 3404, SMD 0.05, -0.02 to 0.12 p = 0.15, I2 = 81%) at end of treatment. Fluoxetine was associated with better neurological scores and less depression. Among the four (n = 3283) high-quality RCTs, the only difference between groups was lower depression scores with fluoxetine.CONCLUSION: This class I evidence demonstrates that fluoxetine does not reduce disability and dependency after stroke but improves depression.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Legg, Lynn
(author)
-
Tilney, Russel
(author)
-
Hsieh, Cheng Fang
(author)
-
Wu, Simiao
(author)
-
Lundström, Erik,1964-Karolinska Institutet,Uppsala universitet,Landtblom: Neurovetenskap,Department of Clinical Neuroscience, Karolinska Institutet(Swepub:uu)erlun676
(author)
-
Rudberg, Ann SofieKarolinska Institutet
(author)
-
Kutlubaev, Mansur
(author)
-
Dennis, Martin S.
(author)
-
Soleimani, Babak
(author)
-
Barugh, Amanda
(author)
-
Hackett, Maree L.
(author)
-
Hankey, Graeme J.
(author)
-
Uppsala universitetLandtblom: Neurovetenskap
(creator_code:org_t)
Related titles
-
In:International Journal of Stroke: SAGE Publications15:4, s. 365-3761747-49301747-4949
Internet link
Find in a library
To the university's database
- By the author/editor
-
Mead, Gillian E.
-
Legg, Lynn
-
Tilney, Russel
-
Hsieh, Cheng Fan ...
-
Wu, Simiao
-
Lundström, Erik, ...
-
show more...
-
Rudberg, Ann Sof ...
-
Kutlubaev, Mansu ...
-
Dennis, Martin S ...
-
Soleimani, Babak
-
Barugh, Amanda
-
Hackett, Maree L ...
-
Hankey, Graeme J ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Neurology
- Articles in the publication
-
International Jo ...
- By the university
-
Uppsala University
-
Karolinska Institutet